Product Name: PT-141

Type: Melanocortin Pathway Research Peptide

Research Focus:

PT-141 (bremelanotide) is a synthetic cyclic heptapeptide and melanocortin receptor agonist (MC3R/MC4R) derived from Melanotan II[1]. It was FDA-approved in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women[2]. Unlike PDE5 inhibitors, PT-141 acts centrally to enhance sexual desire by increasing dopamine release in brain reward and arousal regions[3]. This educational protocol presents on-demand subcutaneous administration using a practical dilution for clear insulin-syringe measurements.

Research Interest:

- Melanocortin receptor activation studies

- Libido and arousal signaling research

- Central nervous system response models

- Behavioral and motivational pathway studies

Scientific Interest:

- Neuroendocrine signaling networks

- Central arousal pathway mechanisms

- Melanocortin system modulation

Reconstitution:

• Reconstitute: Add 3.0 mLbacteriostatic water → ~3.33 mg/mLconcentration.

• FDA-approved dose: 1.75 mg (1750 mcg) at least 45 minutes before anticipated activity.

• Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.

• Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Cycle:

On-Demand Protocol (3 mL = ~3.33 mg/mL)

 Frequency: Inject subcutaneously at least 45 minutes before anticipated sexual activity[2]. Maximum: One injection per 24 hours; no more than 8 injections per month[3]. For doses ≤15 units (≤0.15 mL), consider 30- or 50-unit insulin syringes for improved readability.

IMPORTANT NOTICE:

This product is intended strictly for laboratory research and is not for human or veterinary use. It is not intended to diagnose, treat, cure, or prevent any disease.